Sionna Therapeutics, Inc. (SION) Stock
6 of the hedge funds AlphaScala tracks reported SION in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Viking Global Investors's at $140.56M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own SION?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Viking Global Investors Andreas Halvorsen | 3.20M | $140.56M | n/a |
| Citadel Ken Griffin | 1.15M | $50.48M | -2% |
| Millennium Management Israel Englander | 277K | $12.17M | +97% |
| D.E. Shaw David Shaw | 102K | $4.47M | NEW |
| Point72 Steve Cohen | 49K | $2.17M | -64% |
| Marshall Wace | 13K | $554.2K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Sionna Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 17, 26 | Ra Capital Management, L.P. | Director | SELL | 3.42M | $21.6M |
| Sep 17, 26 | Ra Capital Management, L.P. | Director | SELL | 33.8K | $252K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →SION price chart
Powered by TradingViewWhat does Sionna Therapeutics, Inc. do?
Sionna Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to address cystic fibrosis, a genetic disorder that impacts the respiratory and digestive systems. The company's primary goal is to advance research and therapeutic approaches that restore the balance of chloride ions, pivotal for treating this life-altering condition. Sionna Therapeutics is dedicated to exploring new treatment avenues by leveraging cutting-edge scientific methods and novel chemical entities. Concentrating primarily on the health and pharmaceuticals sector, the company is part of a niche industry aimed at improving health outcomes for patients with chronic and rare diseases. Sionna Therapeutics plays a crucial role in the healthcare market by targeting unmet medical needs, potentially transforming the lives of those affected by cystic fibrosis. With a commitment to innovation and patient care, the company strives to make significant contributions to the field of genetic medicine.